Current evidence and ongoing trials for surgery versus stereotactic body radiation therapy (SBRT) for early-stage non-small cell lung cancer: a narrative review.

ABSTRACT:

Background and objective

Pulmonary resection with mediastinal lymph node dissection is the standard of care for standard-risk operable patients with early-stage non-small cell lung cancer (NSCLC), while stereotactic body radiation therapy (SBRT) is the mainstay treatment for inoperable patients. Within the last decade, SBRT has become increasingly used to treat high-risk operable patients who may otherwise be offered a compromise operation such as wedge resection, as well as standard-risk operable patients who would be able to tolerate lobectomy. The aim of this review is to discuss the current available data comparing SBRT and surgery with an emphasis on the ongoing randomized JoLT-Ca Sublobar Resection (SR) Versus Stereotactic Ablative Radiotherapy (SABR) for Lung Cancer (Stablem

SUBMITTER: Drake L 

PROVIDER: S-EPMC12432671 | biostudies-literature | 2025 Aug

REPOSITORIES: biostudies-literature